- authorisedTherapeutic exploratory (Phase II)
Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy Study.
This study is looking at two medicines, Peginterferon alfa-2a and Ruxolitinib (Jakavi), together for people newly diagnosed with a blood condition called Polycythemia Vera. Researchers want to see how safe this combination is and how well it works.
Denmark - not yet recruitingNA
Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera
This study looks at how Polycythemia Vera (PV) affects your ability to exercise. Researchers want to understand why some people with PV find exercise difficult, by checking blood thickness and fitness levels during an exercise test. This could help tailor exercise plans for people with PV.
France